Latest news
Understanding Immunologic Pathways Builds Clinician Confidence - Dermatology TimesDermatology Times · Mon, 10 Aug 2026 20:30:36 GMTEnvudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 20:09:46 GMTMoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 15:00:26 GMTSonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - Dermatology TimesDermatology Times · Mon, 10 Aug 2026 14:00:21 GMTMoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 13:24:29 GMTCan Apremilast Curb PsA in Patients With Psoriasis? - MedscapeMedscape · Mon, 10 Aug 2026 11:31:29 GMTPsoriasis Immune Rhythms Linked to Disease Severity - EMJEMJ · Mon, 10 Aug 2026 11:28:49 GMTSocrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMT